Add Yahoo as a preferred source to see more of our stories on Google. Are Americans paying nearly $500 for an inhaler that would cost just $7 overseas? U.S. Sen. Tammy Baldwin, D-Wis., says there is a ...
Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
Ipratropium bromide 20mcg, albuterol 100mcg (equivalent to 120mcg albuterol sulfate); per actuation; inhalation spray; CFC-free. Based on studies, ipratropium bromide appears to inhibit vagally ...
As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare ...
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the US Food and Drug Administration (US FDA) has approved Combivent Respimat, a new, propellant-free inhaler product that uses a slow-moving ...
A U.S Senate committee sent letters to four top pharmaceutical companies announcing an investigation into the high prices the companies are charging for inhalers. The Senate committee, in a letter to ...
Combivent Respimat Transition Almost Complete Transition of Combivent Respimat is nearly complete as Boehringer Ingelheim plans to cease distribution of Combivent MDI in May. Boehringer Ingelheim ...
(Reuters) -Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker said on ...
ATLANTA, Georgia — Patients with chronic obstructive pulmonary disease (COPD) experience few adverse events and discontinuations when treated with an ipratropium plus albuterol inhalation spray (CVT-R ...
RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday. BI Pharmaceuticals announced the launch of ...
COMBIVENT MDI and COMBIVENT RESPIMAT are the only short-acting bronchodilator products that offer two different medicines in a single inhaler. Clinical studies in patients with COPD have shown that ...
Are Americans paying nearly $500 for an inhaler that would cost just $7 overseas? U.S. Sen. Tammy Baldwin, D-Wis., says there is a vast difference in the cost of prescriptions in the United States and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results